Cargando…
Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
INTRODUCTION: In severely neutropenic septic acute respiratory distress syndrome (ARDS) patients, macrophages and monocytes are the last potentially remaining innate immune cells. We have previously shown, however, a deactivation of the alveolar macrophage in neutropenic septic ARDS patients. In the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374582/ https://www.ncbi.nlm.nih.gov/pubmed/18282280 http://dx.doi.org/10.1186/cc6791 |
_version_ | 1782154487280959488 |
---|---|
author | Mokart, Djamel Kipnis, Eric Guerre-Berthelot, Pierre Vey, Norbert Capo, Christian Sannini, Antoine Brun, Jean-Paul Blache, Jean-Louis Mege, Jean-Louis Blaise, Didier Guery, Benoit P |
author_facet | Mokart, Djamel Kipnis, Eric Guerre-Berthelot, Pierre Vey, Norbert Capo, Christian Sannini, Antoine Brun, Jean-Paul Blache, Jean-Louis Mege, Jean-Louis Blaise, Didier Guery, Benoit P |
author_sort | Mokart, Djamel |
collection | PubMed |
description | INTRODUCTION: In severely neutropenic septic acute respiratory distress syndrome (ARDS) patients, macrophages and monocytes are the last potentially remaining innate immune cells. We have previously shown, however, a deactivation of the alveolar macrophage in neutropenic septic ARDS patients. In the present study, we tried to characterize in vitro monocyte baseline cytokine production and responsiveness to lipopolysaccharide exposure. METHODS: Twenty-two consecutive patients with cancer were prospectively enrolled into a prospective observational study in an intensive care unit. All patients developed septic ARDS and were divided into two groups: neutropenic patients (n = 12) and non-neutropenic patients (n = 10). All of the neutropenic patients received granulocyte colony-stimulating factor whereas no patient in the non-neutropenic group received granulocyte colony-stimulating factor. We compared monocytes from neutropenic patients with septic ARDS with monocytes from non-neutropenic patients and healthy control individuals (n = 10). Peripheral blood monocytes were cultured, and cytokine levels (TNFα, IL-1β, IL-6, IL-10, and IL-1 receptor antagonist) were assayed with and without lipopolysaccharide stimulation. RESULTS: TNFα, IL-6, IL-10 and IL-1 receptor antagonist levels in unstimulated monocytes were lower in neutropenic patients compared with non-neutropenic patients. Values obtained in the healthy individuals were low as expected, comparable with neutropenic patients. In lipopolysaccharide-stimulated monocytes, both inflammatory and anti-inflammatory cytokine production were significantly lower in neutropenic patients compared with non-neutropenic patients and control individuals. CONCLUSION: Consistent with previous results concerning alveolar macrophage deactivation, we observed a systemic deactivation of monocytes in septic neutropenic ARDS. This deactivation participates in the overall immunodeficiency and could be linked to sepsis, chemotherapy and/or the use of granulocyte colony-stimulating factor. |
format | Text |
id | pubmed-2374582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-23745822008-05-09 Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor Mokart, Djamel Kipnis, Eric Guerre-Berthelot, Pierre Vey, Norbert Capo, Christian Sannini, Antoine Brun, Jean-Paul Blache, Jean-Louis Mege, Jean-Louis Blaise, Didier Guery, Benoit P Crit Care Research INTRODUCTION: In severely neutropenic septic acute respiratory distress syndrome (ARDS) patients, macrophages and monocytes are the last potentially remaining innate immune cells. We have previously shown, however, a deactivation of the alveolar macrophage in neutropenic septic ARDS patients. In the present study, we tried to characterize in vitro monocyte baseline cytokine production and responsiveness to lipopolysaccharide exposure. METHODS: Twenty-two consecutive patients with cancer were prospectively enrolled into a prospective observational study in an intensive care unit. All patients developed septic ARDS and were divided into two groups: neutropenic patients (n = 12) and non-neutropenic patients (n = 10). All of the neutropenic patients received granulocyte colony-stimulating factor whereas no patient in the non-neutropenic group received granulocyte colony-stimulating factor. We compared monocytes from neutropenic patients with septic ARDS with monocytes from non-neutropenic patients and healthy control individuals (n = 10). Peripheral blood monocytes were cultured, and cytokine levels (TNFα, IL-1β, IL-6, IL-10, and IL-1 receptor antagonist) were assayed with and without lipopolysaccharide stimulation. RESULTS: TNFα, IL-6, IL-10 and IL-1 receptor antagonist levels in unstimulated monocytes were lower in neutropenic patients compared with non-neutropenic patients. Values obtained in the healthy individuals were low as expected, comparable with neutropenic patients. In lipopolysaccharide-stimulated monocytes, both inflammatory and anti-inflammatory cytokine production were significantly lower in neutropenic patients compared with non-neutropenic patients and control individuals. CONCLUSION: Consistent with previous results concerning alveolar macrophage deactivation, we observed a systemic deactivation of monocytes in septic neutropenic ARDS. This deactivation participates in the overall immunodeficiency and could be linked to sepsis, chemotherapy and/or the use of granulocyte colony-stimulating factor. BioMed Central 2008 2008-02-18 /pmc/articles/PMC2374582/ /pubmed/18282280 http://dx.doi.org/10.1186/cc6791 Text en Copyright © 2008 Mokart et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Mokart, Djamel Kipnis, Eric Guerre-Berthelot, Pierre Vey, Norbert Capo, Christian Sannini, Antoine Brun, Jean-Paul Blache, Jean-Louis Mege, Jean-Louis Blaise, Didier Guery, Benoit P Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor |
title | Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor |
title_full | Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor |
title_fullStr | Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor |
title_full_unstemmed | Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor |
title_short | Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor |
title_sort | monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374582/ https://www.ncbi.nlm.nih.gov/pubmed/18282280 http://dx.doi.org/10.1186/cc6791 |
work_keys_str_mv | AT mokartdjamel monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT kipniseric monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT guerreberthelotpierre monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT veynorbert monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT capochristian monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT sanniniantoine monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT brunjeanpaul monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT blachejeanlouis monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT megejeanlouis monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT blaisedidier monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor AT guerybenoitp monocytedeactivationinneutropenicacuterespiratorydistresssyndromepatientstreatedwithgranulocytecolonystimulatingfactor |